Report of Foreign Issuer (6-k)
September 26 2016 - 5:23PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT
OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of September, 2016
Commission File Number: 001-37423
Biotie Therapies Oyj
(Exact name of registrant as specified
in its charter)
Biotie Therapies Corp.
(Translation of registrant’s name
into English)
Joukahaisenkatu 6, FI-20520
Turku, Finland
(Address of principal executive office)
Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F:
Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.
|
|
BIOTIE THERAPIES CORP.
|
|
|
|
|
|
|
By:
|
/s/ Kristian Rantala
|
|
|
|
|
Name:
|
Kristian Rantala
|
|
|
|
|
Title:
|
Chief Financial Officer
|
Date: September 26, 2016
EXHIBIT INDEX
Exhibit Number
|
Description
|
99.1
|
Stock Exchange Release dated September 26, 2016 (9:30 a.m. EET): The Arbitral Tribunal has confirmed Acorda Therapeutics, Inc.’s redemption right regarding the shares in Biotie Therapies Corp. and public trading in the shares has been terminated
|